Radiomics Models Derived From Arterial-Phase-Enhanced CT Reliably Predict Both PD-L1 Expression and Immunotherapy Prognosis in Non-small Cell Lung Cancer: A Retrospective, Multicenter Cohort Study
-
Published:2024-07
Issue:
Volume:
Page:
-
ISSN:1076-6332
-
Container-title:Academic Radiology
-
language:en
-
Short-container-title:Academic Radiology
Author:
Liu Zhenhua,
Yao Yimin,
Zhao Miaomiao,
Zhao Qi,
Xue Jiao,
Huang YuhuiORCID,
Qin Songbing
Reference32 articles.
1. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021
2. Pembrolizumab versus chemotherapy for PD-L1–positive non– small-cell lung cancer;Reck;N Engl J Med,2016
3. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer;Borghaei;N Engl J Med,2015
4. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial;West;Lancet Oncol,2019
5. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11);Yang;J Thorac Oncol,2020